Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.60
MDCO's Cash to Debt is ranked higher than
65% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MDCO: 1.60 )
MDCO' s 10-Year Cash to Debt Range
Min: 1.24   Max: No Debt
Current: 1.6

Equity to Asset 0.51
MDCO's Equity to Asset is ranked higher than
57% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. MDCO: 0.51 )
MDCO' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.85
Current: 0.51

0.51
0.85
Interest Coverage 0.85
MDCO's Interest Coverage is ranked lower than
58% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. MDCO: 0.85 )
MDCO' s 10-Year Interest Coverage Range
Min: 0.85   Max: 9999.99
Current: 0.85

0.85
9999.99
F-Score: 4
Z-Score: 1.78
M-Score: -1.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.92
MDCO's Operating margin (%) is ranked higher than
59% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. MDCO: 1.92 )
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44   Max: 14.87
Current: 1.92

-401.44
14.87
Net-margin (%) 2.26
MDCO's Net-margin (%) is ranked higher than
59% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MDCO: 2.26 )
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2   Max: 29.79
Current: 2.26

-385.2
29.79
ROE (%) 1.74
MDCO's ROE (%) is ranked higher than
58% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MDCO: 1.74 )
MDCO' s 10-Year ROE (%) Range
Min: -102.97   Max: 29.26
Current: 1.74

-102.97
29.26
ROA (%) 0.89
MDCO's ROA (%) is ranked higher than
59% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. MDCO: 0.89 )
MDCO' s 10-Year ROA (%) Range
Min: -434.4   Max: 22.07
Current: 0.89

-434.4
22.07
ROC (Joel Greenblatt) (%) 16.54
MDCO's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. MDCO: 16.54 )
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8221.63   Max: 322.98
Current: 16.54

-8221.63
322.98
Revenue Growth (%) 10.10
MDCO's Revenue Growth (%) is ranked higher than
74% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MDCO: 10.10 )
MDCO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 88.9
Current: 10.1

0
88.9
EBITDA Growth (%) -7.90
MDCO's EBITDA Growth (%) is ranked higher than
59% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MDCO: -7.90 )
MDCO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -7.9
Current: -7.9

EPS Growth (%) -49.70
MDCO's EPS Growth (%) is ranked lower than
55% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MDCO: -49.70 )
MDCO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 27.6
Current: -49.7

0
27.6
» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

MDCO Guru Trades in Q1 2013

George Soros 95,000 sh (New)
RS Investment Management 778,319 sh (New)
Vanguard Health Care Fund 472,900 sh (New)
Chuck Royce 3,514,640 sh (+75.9%)
John Hussman 696,000 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 2,335,798 sh (-32.96%)
Jim Simons 10,700 sh (-92.02%)
» More
Q2 2013

MDCO Guru Trades in Q2 2013

Paul Tudor Jones 11,100 sh (New)
Vanguard Health Care Fund 1,331,500 sh (+181.56%)
George Soros 150,000 sh (+57.89%)
Chuck Royce 4,052,665 sh (+15.31%)
RS Investment Management 887,784 sh (+14.06%)
Steven Cohen 140,000 sh (unchged)
Jim Simons Sold Out
John Hussman 513,000 sh (-26.29%)
Steven Cohen 280,876 sh (-87.98%)
» More
Q3 2013

MDCO Guru Trades in Q3 2013

Vanguard Health Care Fund 4,250,415 sh (+219.22%)
George Soros 250,000 sh (+66.67%)
Chuck Royce 4,837,145 sh (+19.36%)
RS Investment Management Sold Out
Paul Tudor Jones 7,300 sh (-34.23%)
Steven Cohen 148,033 sh (-47.3%)
John Hussman 104,000 sh (-79.73%)
» More
Q4 2013

MDCO Guru Trades in Q4 2013

Joel Greenblatt 13,990 sh (New)
Vanguard Health Care Fund 4,599,069 sh (+8.2%)
John Hussman 104,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 4,599,842 sh (-4.91%)
George Soros 50,000 sh (-80%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-12-31 Reduce -80%0.07%$31.48 - $38.91 $ 25.53-29%50000
Joel Greenblatt 2013-12-31 New Buy0.01%$31.48 - $38.91 $ 25.53-29%13990
John Hussman 2013-09-30 Reduce -79.73%0.57%$29.68 - $34.54 $ 25.53-20%104000
Vanguard Health Care Fund 2013-09-30 Add 219.22%0.33%$29.68 - $34.54 $ 25.53-20%4250415
George Soros 2013-09-30 Add 66.67%0.04%$29.68 - $34.54 $ 25.53-20%250000
John Hussman 2013-06-30 Reduce -26.29%0.22%$30.76 - $37.1 $ 25.53-24%513000
Vanguard Health Care Fund 2013-06-30 Add 181.56%0.1%$30.76 - $37.1 $ 25.53-24%1331500
George Soros 2013-06-30 Add 57.89%0.02%$30.76 - $37.1 $ 25.53-24%150000
John Burbank 2013-03-31 Sold Out 0.09%$23.97 - $33.41 $ 25.53-16%0
Vanguard Health Care Fund 2013-03-31 New Buy0.06%$23.97 - $33.41 $ 25.53-16%472900
George Soros 2013-03-31 New Buy0.04%$23.97 - $33.41 $ 25.53-16%95000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 112.30
MDCO's P/E(ttm) is ranked lower than
66% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. MDCO: 112.30 )
MDCO' s 10-Year P/E(ttm) Range
Min: 4.53   Max: 697.27
Current: 112.3

4.53
697.27
P/B 1.80
MDCO's P/B is ranked higher than
77% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. MDCO: 1.80 )
MDCO' s 10-Year P/B Range
Min: 1.14   Max: 11.31
Current: 1.8

1.14
11.31
P/S 2.33
MDCO's P/S is ranked higher than
65% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. MDCO: 2.33 )
MDCO' s 10-Year P/S Range
Min: 0.9   Max: 20.36
Current: 2.33

0.9
20.36
PFCF 23.70
MDCO's PFCF is ranked higher than
70% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.86 vs. MDCO: 23.70 )
MDCO' s 10-Year PFCF Range
Min: 6.54   Max: 305.88
Current: 23.7

6.54
305.88
EV-to-EBIT 111.10
MDCO's EV-to-EBIT is ranked lower than
73% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. MDCO: 111.10 )
MDCO' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 790.2
Current: 111.1

6.6
790.2
Shiller P/E 38.70
MDCO's Shiller P/E is ranked higher than
56% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. MDCO: 38.70 )
MDCO' s 10-Year Shiller P/E Range
Min: 25.91   Max: 748.5
Current: 38.7

25.91
748.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.50
MDCO's Price/DCF (Projected) is ranked higher than
78% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. MDCO: 1.50 )
MDCO' s 10-Year Price/DCF (Projected) Range
Min: 1.08   Max: 5.38
Current: 1.5

1.08
5.38
Price/Median PS Value 0.70
MDCO's Price/Median PS Value is ranked higher than
93% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. MDCO: 0.70 )
MDCO' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 8.28
Current: 0.7

0.32
8.28
Earnings Yield (Greenblatt) 0.90
MDCO's Earnings Yield (Greenblatt) is ranked lower than
65% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MDCO: 0.90 )
MDCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 15.2
Current: 0.9

0.1
15.2
Forward Rate of Return (Yacktman) 1.77
MDCO's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. MDCO: 1.77 )
MDCO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.1   Max: 3.7
Current: 1.77

-6.1
3.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany
Medicines was incorporated in Delaware on July 31, 1996. It is a global biopharmaceutical company focused on saving lives, alleviating suffering and improving the economic efficiency of the world's hospitals. It has four marketed products, Angiomax(bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a topical human recombinant thrombin. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. It also has a pipeline of acute and intensive care hospital products in development, including four late-stage development product candidates, cangrelor, oritavancin, MDCO-157 and IONSYS TM (fentanyl iontophoretic transdermal system), and early stage development product candidates, MDCO-216 and ALN-PCS02 and ALN-PCSsc of its ALN-PCS program. In addition to these products and product candidates, it has a portfolio of ten generic drugs. The Company also co-promotes the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States, as part of its global collaboration agreement with AstraZeneca LP, or AstraZeneca. Angiomax, Recothrom, Cleviprex, ready-to-use Argatroban and its products in development, their stage of development, their mechanism of action and the indications for which they have been approved for use or which they are intended to address. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide